Financial News

Financial Report: Lilly

Newer products contribute to growth in the quarter, while U.S. tax reform results in loss

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Lilly 4Q Revenues: $6.2 billion (+7%) 4Q Loss: $1.7 billion (earnings were $771.8 million 4Q16) FY Revenues: $22.9 billion (+8%) FY Loss: $204.1 million (earnings were $2.7 billion FY16) Comments: Newer products contributed to growth in the quarter. Trulicity sales were $649.0 million, up 93%. Cyramza sales were $204.8 million, up 16%. Basaglar sales were $153.8 million, up 289%. Taltz sales were $172.5 million, up 182%. Jardiance sales were $143.2 million, up 88%. Growth in the quarter was...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters